UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

September 17, 2020

(Commission File No. 001-38475)

ASLAN PHARMACEUTICALS LIMITED

(REG. NO. 289175)

(Translation of registrant’s name into English)

CAYMAN ISLANDS

(Jurisdiction of incorporation or organization)

83 CLEMENCEAU AVENUE

#12-03 UE SQUARE

SINGAPORE 239920

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒ Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes  ☐    No  ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes  ☐    No  ☒

FSC approval of public company status cessation of the Company

On September 17, 2020, ASLAN Pharmaceuticals Limited (the “Company”) received a letter from the Financial Supervisory Commission of Taiwan confirming that the Company is no longer considered a public company in Taiwan. As previously disclosed on Company’s Form 6-K filed with the Securities and Exchange Commission on September 4, 2020, the cessation of public company status in Taiwan was approved by the Company’s shareholders at the second extraordinary general meeting held on September 4, 2020.

The Company’s American Depositary Shares will continue to be listed and traded on the Nasdaq Global Market.